# US 2025/0207118 A1 · Human alpha-galactosidase variants

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0207118 A1
- Document ID: US20250207118A1
- Status: Published application
- Kind: A1
- Application number: 19/080,087
- Filed: 2025-03-14
- Published: 2025-06-26
- Earliest claimed: 2018-12-20
- Assignees: Crosswalk Therapeutics, Inc.
- Applicants: Crosswalk Therapeutics, Inc.
- Inventors: William Casey Hallows; Kristen Jean Vallieu; Nikki Dellas; Yu Zhu; Judy Victoria Antonio Viduya; Chinping Chng; Antoinette Sero; Gjalt W. Huisman; Rachel Cathleen Botham; Moulay Hicham Alaoui Ismaili
- Web page: https://patentgrep.com/patent/US20250207118A1

## CPC

- C12N 9/2465: {acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)}
- C12N 15/52: Genes encoding for enzymes or proenzymes
- C12N 15/85: for animal cells
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 2015/8518: {expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles}
- C12Y 302/01022: Alpha-galactosidase (3.2.1.22)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12Y: ENZYMES

## Abstract

The present invention provides engineered human alpha-galactosidase polypeptides and compositions thereof. The engineered human alpha-galactosidase polypeptides have been optimized to provide improved thermostability, serum stability, improved cellular uptake, stability under both acidic (pH<4) and basic (pH>7) conditions, reduced immunogenicity, and improved globotriaosylceramide removal from cells. The invention also relates to the use of the compositions comprising the engineered human alpha-galactosidase polypeptides for therapeutic purposes.

## Claims

### Claim 1

A recombinant alpha galactosidase A comprising an amino acid sequence comprising at least 95% sequence identity to SEQ ID NO: 252, 292, or 364, wherein the recombinant alpha galactosidase A comprises substitutions at amino acid positions T10P, M39E, L44R, S47T, Y92H, S166P, K206A, F217R, N247D, A261G, H271A, Q302K, L316D, M322I, A337P, W368A, M392T, and S333X, wherein the mutations are relative to SEQ ID NO: 2 and wherein X is Glycine for SEQ ID NO: 292, Phenylalanine for SEQ ID NO: 252, or Asparagine for SEQ ID NO: 364.

### Claim 2 (depends on 1)

The recombinant alpha galactosidase A of claim 1, wherein the amino acid sequence of the alpha galactosidase A comprises SEQ ID NO: 240, 252, 268, 270, 274, 276, 286, 288, 290, 292, 364, or 366.

### Claim 3 (depends on 1)

The recombinant alpha galactosidase A of claim 1, wherein the recombinant alpha galactosidase A exhibits at least one improved property selected from: i) enhanced catalytic activity; ii) increased tolerance to pH 7; iii) increased tolerance to pH 4; iv) increased tolerance to serum; v) increased uptake into cells; vi) increased depletion of globotriaosylceramide from cells; vii) reduced immunogenicity; or a combination of any of i), ii), iii), iv), v), vi), or vii), as compared to SEQ ID NO: 2.

### Claim 4 (depends on 1)

A composition comprising at least one recombinant alpha galactosidase A of claim 1 and a vehicle, excipient or combination.

### Claim 5 (depends on 1)

A recombinant polynucleotide encoding at least one recombinant alpha galactosidase A set forth in claim 1.

### Claim 6 (depends on 5)

An expression vector comprising the recombinant polynucleotide sequence of claim 5 and optionally wherein the recombinant polynucleotide sequence is operably linked to one or more control sequences, wherein the control sequence is a heterologous promoter.

### Claim 7 (depends on 6)

A host cell comprising the expression vector of claim 6.

### Claim 8 (depends on 7)

The host cell of claim 7, wherein the host cell is a mammalian cell.

### Claim 9 (depends on 7)

A method of producing an alpha galactosidase A variant, comprising culturing the host cell of claim 7, under conditions that the alpha galactosidase A encoded by the recombinant polynucleotide is produced.

### Claim 10 (depends on 4)

A pharmaceutical composition for the treatment of Fabry disease, comprising the composition of claim 4.

### Claim 11 (depends on 10)

The pharmaceutical composition of claim 10, wherein the carrier, excipient or combination is a pharmaceutically acceptable carrier, excipient or combination.

### Claim 12 (depends on 10)

The pharmaceutical composition of claim 10, wherein the composition is suitable for parenteral injection or infusion to a human.

### Claim 13 (depends on 1)

The pharmaceutical composition for treating or preventing the symptoms of Fabry disease in a subject having Fabry disease, wherein the pharmaceutical composition comprises at least one recombinant alpha galactosidase A of claim 1, or a recombinant polynucleotide sequence encoding the at least one recombinant alpha galactosidase A, and a pharmaceutically acceptable carrier, excipient or combination.

### Claim 14 (depends on 13)

The pharmaceutical composition of claim 13, wherein the symptoms of Fabry disease are ameliorated compared to untreated Fabry disease symptoms.

### Claim 15 (depends on 13)

The pharmaceutical composition of claim 13, wherein the subject is able to eat a diet that is less restricted in its fat content than diets required by subjects exhibiting the symptoms of Fabry disease.

### Claim 16 (depends on 10)

A method for treating the symptoms of Fabry disease in a subject comprising administering the pharmaceutical composition of claim 10 to a subject having Fabry disease.

### Claim 17 (depends on 16)

The method of claim 16, wherein said symptoms of Fabry disease are ameliorated.

### Claim 18 (depends on 16)

The method of claim 16, wherein aid subject is able to eat a diet that is less restricted in its fat content than diets required by subjects exhibiting the symptoms of Fabry disease.

### Claim 19 (depends on 16)

The method of claim 16, wherein said subject is an infant or child.

### Claim 20 (depends on 16)

The method of claim 16, wherein said subject is an adult or young adult.
